Navigation Links
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
Date:1/18/2012

uct portfolio centered on mature, high selling products to a more diverse portfolio focused on new products. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

Takeda also plans to consolidate its R&D sites to ensure ongoing support for all marketed products and support development and global registration of new products throughout the combined footprint. Takeda will invest strongly in R&D focused on core therapeutic areas, while effectively deploying both internal and external resources to create innovative drugs and transform treatment paradigms. The integrated R&D organization aims to support Takeda's global vision of bringing innovative products to address patients' needs by maximizing efficiency, driving standardization, optimizing resource utilization and driving productivity.  

To meet its goals, Takeda plans the consolidation of a number of sites and functions, including the potential merger or liquidation of subsidiaries mainly in Europe, and a reduction of workforce in the United States, primarily within Takeda Pharmaceuticals North America. The necessary cost for this plan is estimated approximately Yen 70 billion in total during fiscal 2011 - 2015. During this period, Takeda will achieve cost synergies of approximately Yen 200 billion. The cost synergy in Europe estimated in fiscal 2014 is now Yen 40 billion which is 10 billion greater than the original forecast announced in May 2011. Takeda plans a reduction of the Takeda global workforce by approximately 2,800 (2,100 mainly in Europe and 700 in the U.S.) positions by the end of fiscal 2015 across the functions of R&D, commercial, operations and G&A.

Employees affected by the measures will be offered appropriate guidance and support in accordance with Takeda's corpora
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
2. U.S. Food and Drug Administration (FDA) Delays Review of Takedas Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
3. Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
4. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
5. Takeda Completes Acquisition and Names New CEO of Nycomed
6. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
7. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
8. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
9. Takeda to Acquire Nycomed
10. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
11. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ANGELES , July 23, 2014  Researchers from ... with calcium elevates calcium levels too high, ... among other health problems. Women close to ... and vitamin D to prevent diseases such as osteoporosis, ... would recommend that women determine how much calcium they ...
(Date:7/23/2014)... BOSTON , July 23, 2014  The ... CBRX ) will hold a conference call ... for the second quarter ended June 30, 2014. ... July 31, 2014Time: , 8:30 am EDTDial-in numbers: ... (Canada) or,International: (412) 317-0790Webcast (live & archive): , ...
(Date:7/23/2014)... , July 23, 2014  Cardica, Inc. (Nasdaq: ... for its fiscal fourth quarter and year ended June 30, ... Cardica,s management will host a conference call at 4:30 p.m. ... update on the company,s business. Conference Call Details ... at 4:30 p.m. Eastern Time via phone, please dial 866-953-6859 ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 2Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2
... Evergreen Hospital – one of the region,s leaders in ... gallbladder removal in the Washington and Oregon region on ... a procedure just approved by the FDA. ... two patients – a 66-year-old man and a 33-year-old ...
... March of Dimes announced today that Watson Pharmaceuticals has become ... the March of Dimes number one fundraising event, and will ... the organizations will also work to raise awareness of risk ... participating in March for Babies events around the country as ...
Cached Medicine Technology:Evergreen Hospital to Perform Region's First Single-Incision Gallbladder Removal 2Evergreen Hospital to Perform Region's First Single-Incision Gallbladder Removal 3Watson Partners With March of Dimes to Help Fight Preterm Birth 2
(Date:7/23/2014)... study in East Asian women has identified three genetic ... The research, led by Vanderbilt University investigators, was published ... While breast cancer is one of the most common ... risk factors for the disease have focused on women ... heritage and environmental exposures between East Asian women and ...
(Date:7/23/2014)... July 23, 2014 Five years ago, when ... there were few options for babies diagnosed with a medical ... travel across the country for innovative fetal therapies. Since then, ... Institute to care for their babies in the womb, and ... interventions. , “A number of the babies we see ...
(Date:7/23/2014)... Dennis Thompson HealthDay Reporter , ... with salt is associated with double the risk of heart ... risk skyrockets even higher among those whose diabetes isn,t well-managed, ... people with diabetes who consumed an average of 5.9 grams ... disease than those who consumed, on average, 2.8 grams of ...
(Date:7/23/2014)... San Jose, California (PRWEB) July 23, 2014 ... – Biocompatible materials are biodegradable substances exclusively developed ... to repair or replace diseased body tissues. These ... tissue rejection by the host. Global market for ... driven by factors such as technological advancements and ...
(Date:7/23/2014)... Jose, California (PRWEB) July 23, 2014 ... Packaging plays a vital role in the marketing ... product from damage to influencing customers’ purchase decision. ... brand/product differentiation. Intelligent and efficient packaging provides ample ... to invest in advanced packaging technologies such as ...
Breaking Medicine News(10 mins):Health News:Vanderbilt-led study identifies genes linked to breast cancer in East Asian women 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 2Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 3Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 4
... By Randy Dotinga HealthDay Reporter , THURSDAY, ... more evidence that people infected with HIV, the virus that ... as other patients when they undergo kidney transplants. Up ... to HIV patients because of fear that AIDS would quickly ...
... hosting an event on World Aids Day, bringing together some ... future projections for the AIDS pandemic., The panel speakers are ... of Hygiene & Tropical Medicine and former Executive Director of ... Larson, Director of aids2031, an independent consortium set up by ...
... HealthDay Reporter , THURSDAY, Nov. 18 (HealthDay News) ... procedure, can be made more precise by combining a ... Researchers found that a femtosecond laser, used for many ... tissue more cleanly and accurately than manual cataract surgery, ...
... Reporter , WEDNESDAY, Nov. 17 (HealthDay News) -- Using the ... that doctors, prescribing patterns vary across the country in response ... Administration. The result is that patients may be ... live, the researchers said. "We were looking at the ...
... a cardiomyopathy about which little is fully understood, is ... according to a study to be presented Nov. 17 ... in Chicago. The researchers also will report that advanced ... to progress over time in patients with LVNC. ...
... international, multi-center study has revealed the discovery of a novel ... form of eye cancer. Researchers have isolated an oncogene called ... than 40 percent of tumor samples taken from patients with ... November 17, 2010 in the New England Journal of ...
Cached Medicine News:Health News:HIV Patients Do Well After Kidney Transplants: Study 2Health News:HIV Patients Do Well After Kidney Transplants: Study 3Health News:AIDS: Taking a long-term view 2Health News:Study Reports More Precise Way to Remove Cataracts 2Health News:Study Reports More Precise Way to Remove Cataracts 3Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 3Health News:Cardiac MR sheds light on obscure heart muscle condition 2Health News:Novel genetic mutation that causes the most common form of eye cancer discovered 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: